Bluejay Diagnostics Announces Board and Compensation Changes
Ticker: BJDX · Form: 8-K · Filed: 2024-04-02T00:00:00.000Z
Sentiment: neutral
Topics: management-change, compensation
TL;DR
Bluejay Diagnostics shuffled its board and updated exec pay on 3/29.
AI Summary
Bluejay Diagnostics, Inc. announced on March 29, 2024, a change in its board of directors and executive compensation arrangements. The filing details the departure of certain officers and directors, the election of new directors, and updates to compensatory plans.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy, governance, and future financial performance.
Risk Assessment
Risk Level: medium — Changes in leadership and compensation can indicate internal restructuring or strategic shifts that may impact the company's future performance.
Key Players & Entities
- Bluejay Diagnostics, Inc. (company) — Registrant
FAQ
What specific roles have been affected by the departure of officers or directors?
The filing indicates changes in the roles of certain officers and directors but does not specify the exact positions vacated or filled in this summary.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on March 29, 2024.
What is Bluejay Diagnostics, Inc.'s state of incorporation?
Bluejay Diagnostics, Inc. is incorporated in Delaware.
What is the principal executive office address for Bluejay Diagnostics, Inc.?
The address is 360 Massachusetts Avenue, Suite 203, Acton, MA 01720.
What are the main items covered in this 8-K filing?
This filing covers the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers, as well as other events.
Filing Stats: 601 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2024-04-02 17:06:27
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share BJDX The Nasdaq Stock Mar
Filing Documents
- ea0203115-8k_bluejay.htm (8-K) — 27KB
- image_001.jpg (GRAPHIC) — 5KB
- 0001213900-24-029411.txt ( ) — 211KB
- bjdx-20240329.xsd (EX-101.SCH) — 3KB
- bjdx-20240329_lab.xml (EX-101.LAB) — 33KB
- bjdx-20240329_pre.xml (EX-101.PRE) — 22KB
- ea0203115-8k_bluejay_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. Bluejay Diagnostics, Inc. By: /s/ Neil Dey Neil Dey President and Chief Executive Officer Date: April 2, 2024 2